|Ms. Shacey Petrovic||Pres, CEO & Director||1.8M||5.52M||1974|
|Mr. Wayde D. McMillan||Exec. VP,CFO & Treasurer||969.46k||N/A||1970|
|Mr. Charles Alpuche||Exec. VP & COO||1.05M||N/A||1960|
|Mr. Dan Manea||Sr. VP & Chief HR Officer||841.64k||N/A||1967|
|Mr. Bret Christensen||Exec. VP & Chief Commercial Officer||918.47k||N/A||1971|
|Ms. Lauren Budden||VP, Chief Accounting Officer & Controller||N/A||N/A||N/A|
|Ms. Deborah R. Gordon CPA||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Michael Spears||Sr. VP of Regulatory Affairs & Compliance||N/A||N/A||1965|
|Mr. John Wodick Kapples||Sr. VP, Sec. & Gen. Counsel||N/A||N/A||1960|
|Angela Geryak Wiczek||Sr. Director of Corp. Communications||N/A||N/A||N/A|
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Insulet Corporation’s ISS governance QualityScore as of 26 September 2021 is 3. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 7; Compensation: 4.